SOLICITATION NOTICE
B -- Genetic Studies of Osteosarcoma
- Notice Date
- 8/19/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90199-NG
- Archive Date
- 9/18/2009
- Point of Contact
- Malinda L Holdcraft, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
(holdcram@exchange.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis, services for Genetic Studies of Osteosarcoma with Nationwide Children’s Hospital; 700 Children’s Drive, C0837; Columbus, Ohio 43205. The North American Industry Classification System Code is 621511 and the business size standard is $13.5M. The requirement is being processed in accordance with the simplified acquisition procedures as stated in FAR 13.106-1 (b)(1). The purpose of the requirement is to extract genomic DNA from frozen buffy coat samples derived from patients with osteosarcoma. These samples are currently located at the Children’s Oncology Group (COG) at the Nationwide Children’s Hospital. Approximately 975 blood samples from patients with osteosarcoma, treated on COG protocols, are available for study. The samples with sufficient DNA will be used for the genome-wide association study that is currently being conducted at NCI. Period of Performance shall be from award through 12 months. Only one award will be made as a result of this notice. Nationwide Children’s Hospital, COG, is the only source known to the NCI where the blood samples are located. These samples comprise a unique collection, since the vast majority of osteosarcoma patients treated in the United States do so under a treatment protocol run by the COG. Research-related biological samples obtained from these subjects are stored exclusively at the COG BioPathology Center. There is no other extant collection of pre-treatment cryopreserved germline DNA samples from OS patients. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 11am ET September 3, 2009. Questions shall be directed to Malinda Holdcraft, Contract Specialist via fax at 301-402-4513 or via electronic mail holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certification Applications (ORCA), http://orca.bpn.gov. Please reference number NCI-90199-NG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90199-NG/listing.html)
- Record
- SN01917796-W 20090821/090820000504-c5ec88c3434a12e881d29d671d99a9bd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |